Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
September 03, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
August 22, 2024 07:31 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
August 08, 2024 07:00 ET
|
Cognition Therapeutics, Inc.
- Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures - - On Track to...
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
August 05, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the...
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
July 29, 2024 07:00 ET
|
Cognition Therapeutics, Inc.
- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo -- Consistent Positive Changes Across Cognitive and Functional Measures -- Favorable Safety Profile with Most...
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
July 26, 2024 16:11 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
July 02, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
May 21, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
May 07, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
- Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected Mid-2024 -- SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants - PURCHASE, N.Y., May 07,...
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
April 29, 2024 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative...